Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2008 2010 Determine if there is a blood genome profile of children with autism prior to treatment that predicts response to risperdone NIMH PI
2. 2009 Trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism. Autism Speaks Author
3. 2008 2009 Study to investigate the safety and impact on developmental trajectory of 18 months treatment with fluoxetine orally dissolving table (ODT) in childhood and adolescent autistic spectrum disorder. Neuropharm PI
4. 2008 2009 Study of efficacy and safety, followed by an extension open-label study of safety Johnson and Johnson PI
5. 2008 2009 Evaluating the pharmacokinetics of an oral mematine HCI modified- release formulation in pediatric patients with autistic spectrum disorders. Forest PI
6. 2007 2009 Study of the safety and tolerability of aripiprazole flexibly dosed in the treatment of children and adolescents with autistic disorder. Bristol-Myers Squibb PI
7. 2007 2009 Study to investigate the effect of fluoxetine orally dissolving tablet on repetitive behaviors in childhood and adolescent autistic spectrum disorder Autism Speaks Clinical Trials Network PI
8. 2007 2009 Study to investigate the effect of fluoxetine orally dissolving tablet on repetitive behaviors in childhood and adolescent autistic spectrum disorder. Autism Speaks Clinical Trials Network PI
9. 2006 2008 Study with three-fixed doses of aripiprazole in the treatment of children with autistic disorder. Bristol-Myers Squibb PI
10. 2006 2007 Study of escitalopram in pediatric patients with major depressive disorder. Forest PI
11. 2004 2006 Study of the safety and tolerability of quetiapine fumarate (seroquel) immediate-release tablets in daily doses of 400mg to 800mg in children and adolescents with bipolar I disorder and adolescents with schizophrenia Astra Zeneca PI
12. 2004 2006 Study of the flexible-dose oral aripiprazole (2mg or 30mg) in the treatment of adolescent patients with schizophrenia, and children and adolescent patients with bipolar I disorder, manic or mixed episode Otsuka PI
13. 2004 2006 Study with two fixed doses of aripiprazole (10mg or 30mg) in the treatment of adolescent patients with schizophrenia Otsuka PI
14. 2004 2006 Study of the efficacy and safety of quetiapine fumarate (seroquel) immediate-release tablets in daily doses of 400mg to 800mg compared with placebo in the treatment of adolescents with schizophrenia Astra Zeneca PI
15. 2004 2006 Study of the efficacy and safety of quetiapine fumarate (seroquel) immediate-release tablets in daily doses of 400mg to 600mg compared with placebo in the treatment of children and adolescents with bipolar I mania. Astra Zeneca PI
16. 2003 2005 Pharmacokinetics in autism treatment. M.I.N.D. Institute PI
17. 2003 2004 Evaluation of the safety and efficacy of escitalopram in pediatric depression. Forest Laboratories, Inc PI
18. 2003 2004 Study of sertraline and placebo in children and adolescents with posttraumatic stress disorder (PTSD). Pfizer Pharmaceuticals Group PI
19. 2003 2004 Evaluate the safety and efficacy of depakote ER for the Treatment of mania associated with bipolar disorder in children and adolescents. Abbott Laboratories PI
20. 2000 2002 Neurodevelopmental subtyping of autism spectrum disorders. New Jersey Governor’s Council on Autism PI
21. 1998 2002 Study evaluating the efficacy and safety of two fixed dose ranges of buspirone in children with GAD. Bristol-Myers Squibb PI
22. 2000 2001 Study to evaluate the efficacy and safety of Paroxetine in children and adolescents with OCD. SmithKline Beecham, Pharmaceuticals PI
23. 2000 2001 Study of Sertraline in children and adolescents with major depressive disorder. Pfizer, Inc. PI
24. 2000 2001 Study of Tomoxetine Hydrochloride in outpatients with ADHD, ages 6 to 18 years. Lilly Research Laboratories PI
25. 1998 2001 Neurobiological measures of impulse control in sexual offending youth UMDNJ Violence Initiative PI
26. 1999 2000 Evaluation of the safety and efficacy of Citalopram in children and adolescents with depression Forest Laboratories PI
27. 1998 2000 Olanzapine in the treatment of children and adolescents with bipolar disorder: a pilot study Lilly Research Laboratories PI
28. 1998 2000 Olanzapine in the treatment of children with severe emotional disturbance: a pilot study Lilly Research Laboratories PI
29. 1991 1995 Neuropsychophysiologic study of severely disturbed children. NIMH PI
30. 1989 Child and Adolescent Service System Program NIMH PI, Co-Director, and Author
31. 1983 1985 Junior Faculty Development Award NIMH PI
32. 1984 Study psychosocial factors in chronic illness NIMH Active participant
33. 1978 Training grant at George Washington University NIMH PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.